Short answer
MANNKIND CORP (MNKD) filed an 8-K current report with the SEC on May 28, 2026 reporting Item 8.01 (Other Events). FDA released MannKind from Afrezza’s 5-year, 8,000-10,000-patient pulmonary malignancy trial requirement.
MANNKIND CORP 8-K event analysis
AI summary of each reported item and its exhibits
Item 8.01 · Other Events
- FDA released MannKind from Afrezza’s 5-year, 8,000-10,000-patient pulmonary malignancy trial requirement
- Regulatory burden and potential development costs reduced, removing a major postmarketing obligation
- Pediatric Afrezza supplemental BLA remains under FDA review, with a May 29, 2026 PDUFA target date
- INHALE-1st expanded to 10 sites for up to 100 youth participants, with data expected in late 2027
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other MANNKIND CORP 8-K filings
Get the next MNKD 8-K as it lands
Follow MNKD for push alerts, or ask the research agent what this filing means.